sensor in combination with iPro2 (Medtronic, Northridge, CA, USA) is not a real-time (unblinded) CGM, but a retrospective (ie, blinded when wearing) CGM. iPro2 CGM was designed to show data after the maximum of 7 days of wearing, and the data were adjusted mathematically using reference fingerstick glucose values.
The artificial pancreas (AP) STG-55 (Nikkiso CO, LTD, Tokyo, Japan) is a device for the evaluation of glucose metabolism and the management of critically ill patients. 4, 5 AP measures venous blood glucose directly, but it also has a time delay because of a long tubing line (1.0 m) from sampling vessel to the glucose sensor. To date there are no reports that have compared subcutaneous continuous device with an intravenous continuous device at various glucose values.
The aim of the study is to investigate accuracy and time delays of CGM and AP in comparison with PG during acute rising (20 mg/dL/min) to hyperglycemic and euglycemic glucose clamp conditions.
Methods
Seven patients with type 2 diabetes and 2 healthy volunteers were included in this study. We performed 10 tests of experiment: 8 subjects were studied once and 1 subject was studied twice. This study protocol was approved by the Tokushima University Institutional Review Board (#1598) and was in compliance with the World Medical Association's Declaration of Helsinki. All subjects gave written informed consent. The characteristics of subjects are shown in Table 1. CGM (Enlite sensor, Medtronic, Northridge, CA, USA) was attached on the day before the experiment. CGM sensor glucose values were calibrated with venous blood glucose measurement by a point-of-care glucose analyzer IVD, GLUTEST MINT (Sanwa Kagaku Kenkyusho, Kyoto, Japan) just before and after the clamp study. AP system was also calibrated just before the experiment according to the manufacturer's instruction.
After overnight fasting, antecubital vein was cannulated with three catheters in each subject. The first catheter was inserted for venous sampling, the second one was for the infusion of glucose, and the third one was for the insulin infusion. Two catheters were connected to the intravenous continuous glucose monitor of AP and infusion. The total volume of the tubing is 0.9 mL, and the rate of flow is approximately 0.2 mL/min depending on the body weight and blood glucose concentration. STG-55 monitors blood glucose levels using a dual-lumen catheter and a glucose sensor electrode with a glucose oxidase method. Before starting the procedure, two-point internal calibration of AP was performed using two standard solutions (glucose concentration, 0 and 200 mg/dL).
We designed our study with basically the same protocol as our previous report (Gorogawa et al), 6 which was modified from the original report by DeFronzo et al. 7 Hyperglycemic clamp was performed for 90 minutes, followed by euglycemic hyperinsulinemic clamp for 90-120 (90-180 or 210 from the beginning) minutes using AP (Figure 1 ). In detail, infusion of 20% glucose solution was started to raise blood glucose from fasting state to 200 mg/dL within 5 minutes and was followed by hyperglycemic clamp. Soon after hyperglycemic clamp procedure, primed-constant infusion of insulin (starting from 4.62 to 1.45 mU/kg/min) and computer-controlled exogenous infusion of 20% glucose solution were started to achieve the desired steady-state plasma insulin concentrations (100 μU/mL) and to maintain blood glucose levels (100 mg/dL) during euglycemic hyperinsulinemic clamp.
8 PG values were recorded every 5 minutes for the first 15 minutes, and thereafter every 15 minutes during the study period. AP and CGM values were retrospectively analyzed. The time to reach maximum glucose value was recorded during hyperglycemic clamp period. Hyperglycemic clamp was divided into the CGM glucose rising period ("rising period") and 60-90 minutes as the "hyperglycemic plateau period." Euglycemic hyperinsulinemic clamp was divided into 90-150 minutes as the "falling period" and 150-180 or 180-210 minutes as the "euglycemic period." AP and CGM values were compared with PG values using Parkes consensus error grid for type 1 diabetes 9 during the study period. Because the error grid analysis judged the quality of the approximation of reference BG from readings taken at isolated static points in time, regardless of the temporal structure of the data as reported by Kovatchev et al. 10 The error matrix, which combines rate error grid analysis zones and point error grid analysis zones, in each period of AP and CGM were calculated according to Kovatchev et al. 10 A comparison of mean absolute rate difference (MARD [%]) of glucose values with PG between AP and CGM in each period was calculated as previously reported.
11
Plasma insulin levels were measured in the laboratory of Tokushima University Hospital using the fluorescenceenzyme immunoassay procedure (Tosoh Corp, Tokyo, Japan).
Statistical Analysis
Glucose values were not normally distributed; they were analyzed using nonparametric tests. Glucose values of CGM and AP were compared with PG values using nonparametric Mann-Whitney U tests. The differences in glucose values of each clamp period of CGM, AP, and PG values were evaluated using one-way repeated-measures ANOVA, with Bonferroni-Holm-adjusted post hoc tests for multiple comparisons. P values of less than .05 were considered statistically significant. Statistical analyses were performed using SPSS software version 21 (SPSS, Chicago, IL, USA).
Results
Seven patients with type 2 diabetes and 2 healthy volunteers were enrolled in this study. PG values between these patients and volunteers were similar at fasting state and during hyperglycemic clamp in our study.
AP Figure  1 ). The CGM glucose values rose until 45 minutes during the hyperglycemic clamp period; therefore, we defined the 0-45 minute period as the rising period. As evaluated with oneway ANOVA, AP and CGM values during the rising period and hyperglycemic period were significantly lower than PG values (Table 2) . CGM values during hyperglycemic plateau period were significantly lower than PG values (Table 2) . AP, CGM, and PG values were not different between these groups during the falling period and euglycemic plateau period ( Table 2 ). The time delays of AP values to reach maximum glucose levels were comparable with PG values and the time delays of CGM values to reach maximum glucose levels were significantly higher than PG values (Table 3 ).
The differences between AP, CGM, and PG values in the whole experiment were shown in Figure 2 . Of CGM and AP values, 95% were within the zones A and B in the Parkes consensus error grid (Figure 2 ). The distributions of Parkes consensus error grid of AP and CGM in each period were investigated. The distributions of zone A in AP values were significantly higher than in CGM values during rising period (Figure 3 ). Zone A in CGM was higher than AP values during the falling period according to the error matrix10 in each period of AP and CGM (Supplementary Table) . MARD for the rising period was significantly lower in AP than CGM (15.3 ± 4.6 vs 24.0 ± 7.6, P < .05); however, there were no difference between the MARD of AP and CGM in the other time periods (Table 4) .
Discussion
We investigated herein the accuracy and time delays of CGM and AP in comparison with PG during acute rising (20 mg/ dL/min) to hyperglycemic and euglycemic glucose clamp conditions. Hyperglycemic clamp was designed to raise PG from approximately 100 to 200 mg/dL within 5 minutes, which equates to an average rate of 20 mg/dL/min, so this trial does not represent blood glucose fluctuation in real life. AP and CGM values were supposed to show the same glucose values as PG values; however, both of these values were behind PG values during the acute rising period.
To our knowledge, this is the first study to compare AP, CGM, and PG values during nonphysiological glucose rising of hyperglycemic clamp followed by euglycemic hyperinsulinemic clamp. CGM values did not catch up to PG values during the rising period or the hyperglycemic period. There are several reasons for this phenomenon. CGM values were calibrated with two reference points, which were just before and after the experiment in this study. This indicates that retrospective mathematical smoothing, that is, adjustment to values to show an even curve, delayed CGM values during the rising period, which might have led to the higher CGM values at the beginning of hyperglycemic clamp and the lower CGM values during this period. It is reported that the mean (standard deviation) time delay of the CGM values to blood glucose meter was 9.5 (3.7) minutes. 12 The time to catch up to maximum glucose of CGM values in this study was more delayed than in the previous report. This may also account for the delay during the acute rising of glucose.
AP values were significantly lower during the rising period in several points (Figure 1 ). It might be because of the time lag of the AP system due to the length of the tubing set during clamp procedure is approximately 4-5 minutes. However, AP values were not statistically delayed compared with PG values using multiple comparison method (Table 2) . This rising speed is far faster than the previous report, which describes the comparison of PG and CGM values during hyperglycemic clamp by Monsod et al. 13 It might not be necessary for CGM to catch up for these conditions.
The previous reports by Morrow et al 14 compared AP and CGM during steady state in variable glucose clamp, and they found CGM was accurate from 50-250 mg/dL. They used Biostator CGIIs as the AP system, while we used STG-55, which is the only available bedside AP in Japan. The study design was quite different from the previous study by Morrow et al in the view of changing speed of glucose concentration. The blood glucose was raised up by 20 mg/dL/ min in our study; however, it was raised up by 2 mg/dL/min in the previous study. So the raising speed of blood glucose was 10 times faster than in the previous report. Although MARD values were not so different from Morrow et al's report, there might be another index to be evaluated. Medtronic's sensor response is limited by filtering algorithms to be no more than 3 mg/dL/min. 15 Our protocol is to raise up blood glucose levels 100 mg/dL within 5 minutes, so the delay of the CGM sensor glucose value compared to PG value was expected to be more than their report. There also might have been a streaming/mixing effect, and also the sensor in the AP device is in the center of the AP system. There must have been a time delay because of the tubing. However, there is no other smaller tubing available for the current STG-55 system. We could not test smaller tubing.
On the other hand, AP and CGM values were not different as PG values during rest of the periods (Table 2 ). These rest of the periods were almost usual physiological blood glucose change. Both CGM and AP may be able to catch up with glucose change in the most of daily life.
Zone A and zone B in the Parkes consensus error grid have been regarded as clinically acceptable. 9 Although AP and CGM values were significantly different from PG values, more than 99% of AP and CGM values were within zone A and zone B (Figure 2 ). This indicates that AP and CGM values were at least clinically safe to use. However, the distribution of zone A in AP was significantly higher than CGM during the rising period according to precise investigation ( Figure 3) . These results indicate that AP reflects the glucose change better than CGM during rapid glucose change. On the other hands, zone A of the error matrix10 during falling period, AP seems worse than CGM; this may be because of automatic smoothing of the CGM computer algorithm (see Supplementary Table) .
We performed 10 tests of experiment: 8 subjects were studied once and 1 subject was studied twice; however, the number of subjects was small. There are several questions left for this experiment. If we change the calibration time to a very distant time from the experimental period, do the results remain the same? Also, if we use real-time CGM sensors, do they perform the same way? These questions are left for future research.
Conclusions
Both CGM and AP did not follow nonphysiological acute glucose rising, but matched well during physiological glucose-lowering change.
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